Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 23599678)

2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.

O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A.

Clinicoecon Outcomes Res. 2013 Sep 13;5:459-70. doi: 10.2147/CEOR.S47990. eCollection 2013.

4.

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).

Barnett AH, Millar HL, Loze JY, L'Italien GJ, van Baardewijk M, Knapp M.

Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):239-47. doi: 10.1007/s00406-008-0863-2. Epub 2009 Mar 9.

PMID:
19267255
5.
6.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Oct;105(1-3):175-87. doi: 10.1016/j.schres.2008.07.006. Epub 2008 Sep 4.

7.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

8.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
9.

Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.

Jerrell JM, McIntyre RS, Tripathi A.

Clin Schizophr Relat Psychoses. 2010 Oct;4(3):161-8. doi: 10.3371/CSRP.4.3.2.

PMID:
20880826
10.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
11.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
12.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.
14.

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.

Colombo GL, Caruggi M, Di Matteo S, Rossi A.

Neuropsychiatr Dis Treat. 2008 Oct;4(5):967-76. Erratum in: Neuropsychiatr Dis Treat. 2008 Dec;4(6):1283.

15.

Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.

Hansen RA, Maciejewski M, Yu-Isenberg K, Farley JF.

Psychiatr Serv. 2012 Sep 1;63(9):920-8. doi: 10.1176/appi.ps.201100328.

PMID:
22706887
16.

Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.

Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL.

Pharmacoeconomics. 2003;21(10):683-97.

PMID:
12828491
17.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
18.
19.
20.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):45-53. Epub 2005 Sep 28.

PMID:
16198088
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk